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The possible association of specific fatty acid (FA) intake and pancreatic cancer risk was investigated in a population-based case–
control study of 462 histologically confirmed cases and 4721 frequency-matched controls in eight Canadian provinces between 1994
and 1997. Dietary intake was assessed by means of a self-administered food frequency questionnaire. Unconditional logistic
regression was used to assess associations between dietary FAs and pancreatic cancer risk. After adjustment for age, province, body
mass index, smoking, educational attainment, fat and total energy intake, statistically significant inverse associations were observed
between pancreatic cancer risk and palmitate (odds ratios (ORs)¼0.73; 95% confidence intervals (CIs) 0.56–0.96; P-trend¼0.02),
stearate (OR¼0.70; 95% CI 0.51–0.94; P-trend¼0.04), oleate (OR¼0.75; 95% CI 0.55–1.02; P-trend¼0.04), saturated FAs
(OR¼0.67; 95% CI 0.50–0.91; P-trend¼0.01), and monounsaturated FAs (OR¼0.72; 95% CI 0.53–0.98; P-trend¼0.02), when
comparing the highest quartile of intake to the lowest. Significant interactions were detected between body mass index and both
saturated and monounsaturated FAs, with a markedly reduced risk associated with intake of stearate (OR¼0.36; 95% CI 0.18–0.70;
P-trend¼0.001), oleate (OR¼0.36; 95% CI 0.19–0.72; P-trend¼0.002), saturated FAs (OR¼0.35; 95% CI 0.18–0.67;
P-trend¼0.002), and monounsaturated FAs (OR¼0.32; 95% CI 0.16–0.63; P-trendo0.0001) among subjects who are obese. The
results suggest that substituting polyunsaturated FAs with saturated or monounsaturated FAs may reduce pancreatic cancer risk,
independently of total energy intake, particularly among obese subjects.
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Pancreatic cancer represents the fourth leading cause of cancer-
related deaths in Canada (CCS, 2004), and is among the most
rapidly fatal cancer worldwide (WHO/IARC, 2003). The prognosis
of subjects with pancreatic cancer is extremely poor since
diagnosis is usually late due to lack of symptoms. The median
survival time, regardless of therapy, is about 2–3 months after
diagnosis, with a 5-year survival of about 4% (Ries et al, 2002).
Experimental studies of pancreatic cancer indicate that while
dietary fat per se does not cause pancreatic cancer (Roebuck,
1992), individual polyunsaturated fatty acids (FAs), but not
monounsaturated or saturated FAs, have an inhibitory effect on
the growth of human pancreatic cancer cell lines (Falconer et al,
1994), suggesting that an association between dietary fats
and pancreatic cancer may depend on the level of specific FA
intake.
An elevated risk of pancreatic cancer in relation to high dietary
total fat (Durbec et al, 1983; Ghadirian et al, 1991; Howe and
Burch, 1996) and saturated fat intake (Ghadirian et al, 1991; Howe
and Burch, 1996; Stolzenberg-Solomon et al, 2002) has been
reported. Although no association with total or saturated fat intake
has been found (Farrow and Davis, 1990; Kalapothaki et al, 1993),
a significant decrease in risk with higher saturated (Bueno de
Mesquita et al, 1990, 1991; Zatonski et al, 1991; Ji et al, 1995;
Silverman et al, 1998), monounsaturated (Bueno de Mesquita et al,
1990; Zatonski et al, 1991), and polyunsaturated (Zatonski et al,
1991) fat intake has been reported. A recent cohort study found no
significant association in relation to specific FAs (Michaud et al,
2003), but included less than 180 cases over 18 years of follow-up.
The present case–control study, based on data from the Canadian
National Enhanced Cancer Surveillance System (NECSS),
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The NECSS is a multi-site, population-based, case–control study
involving 21022 participants with one of 19 types of cancer
identified through cancer registries in eight of the 10 Canadian
provinces, namely Alberta, British Columbia, Manitoba, New-
foundland, Nova Scotia, Ontario, Prince Edward Island, and
Saskatchewan. The present investigation includes only pancreatic
cancer cases, and is restricted to data obtained from direct (rather
than proxy) interviews. The study population has been described
in detail elsewhere (Villeneuve et al, 2000). Briefly, between April
1, 1994 and December 31, 1997, the participating provincial
registries identified pancreatic cancer cases as early as possible in
the registration process, to minimise the loss of subjects from this
rapidly fatal disease. All pancreatic cancer cases included in the
NECSS were confirmed histologically, and defined according to the
WHO’s International Classification of Diseases, rubric 157 (WHO,
1985). Like most other studies of pancreatic cancer, the proportion
of cases subject to direct interview was low. Among men diagnosed
with pancreatic cancer, 30% had died before an interview could be
conducted, and consent was not granted by physicians for an
additional 15%. Among women, 28% had died before they could be
contacted, and the attending physician refused consent to
approach patients for an additional 16%. The vast majority of
cases were ascertained within 1–3 months of diagnosis; physician
consent to contact patients was generally obtained within 1 month,
and approximately 70% of questionnaires were returned within 2
months of mailing. Response rates of eligible cases were 55% for
men and 56% for women.
The NECSS used frequency matching in selecting the control
population to achieve age and gender distributions similar to those
of all cancer cases combined. Based on the projected number of
incident cancer cases by province, the questionnaires were mailed
to 8117 subjects during the 1996 calendar year using the same
protocol as for cases. Questionnaires were not returned for 573
controls (7.4%) because of incorrect or changed addresses.
Strategies for control selection varied by province, depending on
data accessibility. In Prince Edward Island, Nova Scotia, Manitoba,
Saskatchewan, and British Columbia, provincial health insurance
plans were tapped to obtain a random sample of the provincial
population stratified by age and gender. In each of these provinces,
more than 95% of residents are covered by public health care
plans. Active military personnel and their families as well as
indigenous peoples were excluded because they were covered by
other plans. In Ontario, Ministry of Finance data were used to
derive a stratified random sample, while Newfoundland and
Alberta adopted a random digit-dialling method to enrol a
population-based sample of controls. A total of 5039 controls
were selected to serve as a common control group for all types of
cancer. Response rates of 65 and 71% were achieved from the
respective male and female control populations.
Questionnaires, with telephone follow-up for clarification when
necessary, were mailed to subjects to obtain information on
residential and occupational history and other risk factors for
cancer. The NECSS questionnaire included questions on smoking
history, height, weight, physical activity, and educational attain-
ment.
Dietary assessment
Food consumption data were obtained via a semi-quantitative food
frequency questionnaire (FFQ) developed after two instruments
that have been widely validated previously: the short Block
questionnaire (Block et al, 1990) and the Willett questionnaire
(Willett, 1998). Subtle changes were made to the questionnaire
items to take into account differences in American and Canadian
dietary practices. The FFQ includes questions on 69 different food
and beverage items, including the frequency of consumption and
the amounts consumed. Participants were asked how often they
had consumed these foods per week in the period 2 years prior to
interview. Daily FA intakes were determined by summing the FA
content of each food and beverage item in the FFQ, based on
reference values given in the 1997 Canadian Nutrient File (CNF).
Statistical analysis
Data were collected on 475 cases (264 men, 211 women) and 4802
controls (2377 men, 2425 women). We excluded subjects with daily
energy intake o500kcal (10 cases and 54 controls) or 45000kcal
(three cases and 27 controls) because such intakes are unrealistic
and hence of questionable validity. Finally, a total of 462 cases (258
men, 204 women) and 4721 frequency-matched controls (2331
men, 2390 women) were eligible for analysis.
Food intake among the cases and controls was converted to
specific FA intake based on the CNF. To determine the associations
between dietary FA intakes and pancreatic cancer risk, the study
subjects were divided into four categories according to quartiles of
calorie-adjusted FA intake in the control population. Odds ratios
(ORs) and associated 95% confidence intervals (CIs) were
calculated based on unconditional logistic regression. Risk
estimates were adjusted for matching variables (age group and
province), lifetime cigarette consumption (0, 40–15, and 415
pack-years), body mass index (BMI) (o25, 25–29.9, and
X30kgm
 2), educational attainment (years), total fat intake
(gday
 1), and total energy intake. To evaluate effect modification
by BMI, age, educational attainment, smoking, and physical
activity, the P-value for a multiplicative interaction term added
to the fully adjusted model was examined – and when it was
statistically significant, the analysis was stratified on that variable.
Tests for linear trend in the variables included in logistic
regression models were performed with scores derived from the
median values of categorised variables, and entered into the model
as successive integers. All tests of statistical significance were two-
sided. Data analysis was performed using SPSS for WINDOWS
(release 10.02, 1999; SPSS Inc., Chicago, IL, USA).
RESULTS
Selected characteristics of the study population are presented in
Table 1. The age distributions of cases and controls were somewhat
similar although there was a slight excess of younger control
subjects, and cases were more likely to consume high amounts of
tobacco. Two years prior to the diagnosis of cancer, a tendency
towards heightened pancreatic cancer risk with increased BMI was
noted, while there were no appreciable differences between cases
and controls with respect to physical activity. Cases were more
likely to have higher fat intake and greater total energy intake than
controls.
The major sources of butyric acid were milk and icecream.
Lauric acid, stearic acid, and saturated FAs were derived primarily
from butter and cheese. Palmitic acid was mainly supplied by
bacon, while oleic acid, linoleic acid, and alpha-linolenic acid were
derived from nuts and butter, nuts and chips, and mayonnaise,
respectively. Arachidonic acid was from fish and chicken,
eicosapentaenoic acid and docosahexaenoic acid were exclusively
from fish, while trans FAs were from margarine and mayonnaise.
The relationships between lifestyle variables and selected FAs
are summarised in Table 2. Age was positively associated with both
palmitate and saturated FAs, and inversely associated with oleate
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yand monounsaturated FAs, but not with stearate. BMI was
inversely related to palmitate, saturated and monounsaturated
FAs, but not to stearate or oleate. Smoking was positively linked
with palmitate, stearate, oleate, saturated and monounsaturated
FAs. Educational attainment was positively associated with
palmitate and inversely associated with stearate, but not with
oleate, saturated or monounsaturated FAs. Total fat intake was
positively related to stearate, oleate, saturated and monounsatu-
rated FAs, but inversely related to palmitate.
Table 3 presents the ORs and corresponding 95% CIs for
pancreatic cancer according to categories of dietary FA intakes.
After adjustment for age, province, educational attainment,
smoking, BMI, total fat, and total energy intake, a significant
inverse association was observed in women between pancreatic
cancer risk and palmitate (OR¼0.73; 95% CI 0.56–0.96; P-
trend¼0.02), stearate (OR¼0.70; 95% CI 0.51–0.94; P-tren-
d¼0.04), oleate (OR¼0.75; 95% CI 0.55–1.02; P-trend¼0.04),
total saturated FAs (OR¼0.67; 95% CI 0.50–0.91; P-trend¼0.01),
and monounsaturated FAs (OR¼0.72; 95% CI 0.53–0.98; P-
trend¼0.02), when comparing the highest quartile of intake to the
lowest.
There was a significant interaction between BMI and stearic acid
(P¼0.04) as well as oleic acid (P¼0.04), and both total saturated
and monounsaturated FAs (P¼0.05). The risk of pancreatic cancer
in relation to intake of stearate, oleate, total saturated and
monounsaturated FAs is presented in Table 4 by categories of
BMI. Among obese subjects, strong and significant inverse
associations were apparent between stearic acid (OR¼0.36; 95%
CI 0.18–0.70; P-trend¼0.001), oleic acid (OR¼0.36; 95%
CI¼0.19–0.72; P-trend¼0.002), saturated FAs (OR¼0.35; 95%
CI 0.18–0.67; P-trend¼0.002), and monounsaturated FAs
(OR¼0.32; 95% CI 0.16–0.61; P-trend¼0.001) and pancreatic
cancer risk, when comparing the highest to the lowest quartile of
intakes. There was no evidence of effect modification by age,
educational attainment, smoking, and physical activity (P for
interaction 40.05 in all cases, data not shown).
DISCUSSION
In this population-based case–control study of specific FAs and
pancreatic cancer, we found that palmitic acid, stearic acid, and
total saturated FA intakes were associated with a significantly
decreased risk. Our findings are in agreement with those of five
previous case–control studies that reported statistically significant
or borderline decreased risks of pancreatic cancer with higher
saturated fat intake, with a relative risk of 0.3 (95% CI 0.1–0.8), 0.3
(95% CI 0.1–1.0), 0.2 (95% CI 0.1–0.2), and 0.9 (P-trend¼0.028;
for men) for intakes in the highest as compared to the lowest
quartiles (Baghurst et al, 1991; Bueno de Mesquita et al, 1991;
Zatonski et al, 1991; Silverman et al, 1998), respectively. A large
collaborative population-based case–control of pancreatic cancer
comprising 802 cases from five countries in the Surveillance of
Environmental Aspects Related to Cancers in Humans (SEARCH)
Study found a nonsignificant reduced risk, with an overall OR of
0.8 (95% CI 0.6–1.2) for the highest quartile of saturated fat intake
(Howe et al, 1992), with significant inverse associations reported in
two study centres (Howe and Burch, 1996).
In contrast, three case–control and two cohort studies reported
no significant association (Kalapothaki et al, 1993; Howe and
Burch, 1996; Michaud et al, 2003) or an increased risk asso-
ciated with higher saturated fat intake (Ghadirian et al, 1991;
Stolzenberg-Solomon et al, 2002). The latter investigations
reporting an increased risk utilised specific populations such as
French Canadians or male smokers who may have particular food
habits and dietary patterns. Levels of saturated FA intakes were
substantially higher in the case–control by Ghadirian et al and in
the cohort study by Stolzenberg–Solomon et al. The mean
Table 1 Selected characteristics of the study population (n¼5183),
National Enhanced Cancer Surveillance System, Canada, 1994–1997
Cases (n¼462) Controls (n¼4721)
Characteristic n % n %
Age (years)
30–34 5 1 186 4
35–39 8 2 264 6
40–44 18 4 333 7
45–49 28 6 448 9
50–54 48 10 426 9
55–59 58 13 486 11
60–64 85 18 701 15
65–69 115 25 914 19
70–74 97 21 963 20
Cigarette consumption (pack-years)
0 144 31 1767 38
40–15 93 20 1384 29
415 219 48 1517 32
Missing 6 1 53 1
BMI 2 years prior to diagnosis (kgm
 2)
o25 188 41 2235 47
25–29.9 173 37 1816 39
X30 101 22 670 14
Physical activity (total number of hoursweek
 1)
o21 135 29 1168 25
21–23 228 49 2550 54










a,bThese differences are significant, Po0.001.
Table 2 Relationships between selected lifestyle factors and calorie-adjusted fatty acid intakes




*  0.96 (0.3)
w 0.26 (0.1)
w 0.12 (0.4)
*  4.27 (1.4)
*
Stearate  0.11 (0.1)  0.14 (0.2) 0.28 (0.0)
w  0.49 (0.2)
* 85.10 (0.7)
w
Oleate  0.32 (0.1)
w 0.25 (0.1) 0.13 (0.0)
w 0.04 (0.2) 89.00 (0.6)
w
Saturated FAs 0.15 (0.1)
*  0.53 (0.2)
* 0.12 (0.0)
*  0.11 (0.2) 82.00 (0.8)
w
Monounsaturated FAs  0.32 (0.1)
w 0.21 (0.1) 0.12 (0.0)
w 0.04 (0.2) 90.70 (0.6)
w
aFA¼fatty acid. Parameter estimates (b coefficient and standard error in %) from regression with palmitate, stearate, oleate, saturated and monounsaturated FAs as dependent
variables and age, BMI, smoking, educational attainment and total fat intake as independent variables.
*Po0.05.
wPp0.001.
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a and 95% CIs for pancreatic cancer associated with dietary fatty acids
Fatty acid
Quartiles of fatty acid intakes
P-trend Q1 Q2 Q3 Q4
Butyric acid
Median (gday
 1) 0.5 0.5 5 31
Cases/controls 134/1180 124/1181 92/1181 112/1179
Multivariate OR (95% CI) 1.00 1.07 (0.81–1.42) 0.78 (0.57–1.05) 0.94 (0.70–1.25) 0.62
Lauric acid
Median (gday
 1) 0.2 0.3 0.4 1
Cases/controls 116/1180 113/1180 103/1181 130/1180
Multivariate OR (95% CI) 1.00 0.99 (0.75–1.32) 0.92 (0.69–1.23) 0.92 (0.70–1.22) 0.56
Palmitic acid
Median (gday
 1) 7.7 7.7 12 37
Cases/controls 142/1180 100/1182 107/1179 113/1180
Multivariate OR (95% CI) 1.00 0.70 (0.53–0.93) 0.74 (0.56–0.97) 0.73 (0.56–0.96) 0.02
Stearic acid
Median7s.d. (gday
 1) 2.7 3.1 3.9 6.8
Cases/controls 123/1180 107/1180 111/1181 121/1180
Multivariate OR (95% CI) 1.00 0.81 (0.61–1.08) 0.82 (0.62–1.09) 0.70 (0.51–0.94) 0.04
Oleic acid
Median (gday
 1) 13.7 14.6 17.8 28.4
Cases/controls 121/1180 112/1115 100/1181 125/1180
Multivariate OR (95% CI) 1.00 0.91 (0.69–1.20) 0.78 (0.59–1.04) 0.75 (0.55–1.02) 0.04
Linoleic acid
Median (gday
 1) 4.2 4.5 5.6 8.7
Cases/controls 122/1180 111/1181 108/1180 121/1180
Multivariate OR (95% CI) 1.00 0.93 (0.70–1.23) 0.90 (0.68–1.19) 0.88 (0.66–1.17) 0.28
Alpha-linolenic acid
Median (gday
 1) 0.6 0.6 1.1 1.9
Cases/controls 106/1180 123/1180 115/1181 118/1180
Multivariate OR (95% CI) 1.00 1.20 (0.90–1.57) 1.10 (0.83–1.47) 0.99 (0.74–1.33) 0.71
Eicosapentaenoic acid (EPA)
Median (gday
 1) 0.03 0.03 0.04 0.13
Cases/controls 119/1180 108/1181 122/1180 113/1180
Multivariate OR (95% CI) 1.00 0.99 (0.75–1.33) 1.16 (0.88–1.54) 1.10 (0.82–1.47) 0.52
Docosahexaenoic acid (DHA)
Median (gday
 1) 0.02 0.07 0.13 0.37
Cases/controls 117/1180 105/1182 120/1179 120/1180
Multivariate OR (95% CI) 1.00 0.96 (0.72–1.28) 1.12 (0.84–1.48) 1.16 (0.876–1.54) 0.30
Arachidonic acid
Median (gday
 1) 0.02 0.04 0.05 0.08
Cases/controls 116/1180 109/1180 118/1181 119/1180
Multivariate OR (95% CI) 1.00 0.96 (0.73–1.28) 1.05 (0.80–1.38) 0.96 (0.73–1.27) 0.85
o-3 FAs (EPA+DHA)
Median (gday
 1) 0.02 0.09 0.18 0.50
Cases/controls 117/1180 107/1181 122/1180 116/1180
Multivariate OR (95% CI) 1.00 0.97 (0.73–1.30) 1.14 (0.86–1.52) 1.12 (0.84–1.50) 0.40
Saturated FAs
Median (gday
 1) 11.2 12.5 15.7 28.8
Cases/controls 127/1180 110/1180 108/1181 117/1180
Multivariate OR (95% CI) 1.00 0.83 (0.63–1.09) 0.79 (0.60–1.04) 0.67 (0.50–0.91) 0.01
Monounsaturated FAs
Median (gday
 1) 13.6 15.4 19.0 30.3
Cases/controls 122/1180 116/1181 101/1180 123/1180
Multivariate OR (95% CI) 1.00 0.88 (0.67–1.16) 0.76 (0.57–1.02) 0.72 (0.53–0.98) 0.02
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ysaturated fat intake among French-Canadians was 55.27
40.6gday
 1 for cases and 42.2727.0gday
 1 for controls com-
pared with 18.2711.3gday
 1 for cases and 20.0713.7 for controls
in our study. The median saturated fat intake among male smokers
was 61.8gday
 1 for cases and 58.5gday
 1 for nonaffected,
compared with 16.2gday
 1 for cases and 15.3gday
 1 for controls
in the present investigation; this observation may partly explain
the lack of consistency among these studies.
Palmitate and stearate are the most common long-chain
saturated FAs. The dietary intake of these two specific was related
to 27–30% risk reduction, and a 33% decrease in pancreatic cancer
risk with total saturated FA intake. The mechanisms by which
these relationships may be explained are areas of current active
research. A high fat intake affects pancreatic cancer risk by
stimulating cholecystokinin (CCK) release, which, in rodents,
increases susceptibility to carcinogens and causes acinar cell
hyperplasia, followed by the development of pancreatic carcino-
mas (Longnecker, 1993; Chu et al, 1997). In humans, it has been
suggested that duodenal CCK release might differ significantly
according to the degree of fat saturation, with unsaturated FAs
being stronger stimulants of CCK release than saturated FAs
(Beardshall et al, 1989). In response to meals containing different
fats, CCK release is enhanced by one-, two-, and six-fold for
saturated, monounsaturated, and polyunsaturated FAs, respec-
tively. If the hypothesis that the promoting effect of dietary fat on
pancreatic carcinogenesis is mediated via CCK is correct, this
could partly explain the reduced pancreatic cancer risk associated
with both specific and total saturated FAs.
Oleic acid is a major monounsaturated FA. We found a 25%
(statistically significant) risk reduction related to oleate intake,
with monounsaturated FA intake associated with a 28% decrease
in pancreatic cancer risk. One case–control study (Zatonski et al,
1991) in Poland found a strong decrease in pancreatic cancer risk
(OR¼0.10; P-trend¼0.02) with higher monounsaturated fat
intake. Another case–control study (Bueno de Mesquita et al,
1990) in the Netherlands reported a 60% nonsignificant decrease in
risk among men, but not among women. Other studies have
detected no statistically significant association with monounsatu-
rated FAs (Howe et al, 1990; Michaud et al, 2002).
Few risk factors for pancreatic cancer have been consistently
identified. In the present study age, BMI, smoking, educational
attainment, and total fat intake were clearly related to palmitate,
stearate, oleate, saturated and monounsaturated FAs. We found
that adjustments increased the magnitude of the association
between these FAs and pancreatic cancer risk. Therefore, it is likely
that the factors we included in the model are simultaneously
confounding and may be responsible for this effect.
Pancreatic cancer risk reduction in relation to dietary intake of
stearic acid, oleic acid, and both total saturated and monounsa-
turated FAs remained evident among obese subjects. Saturated and
Table 3 (Continued)
Fatty acid
Quartiles of fatty acid intakes
P-trend Q1 Q2 Q3 Q4
Polyunsaturated FAs
Median (gday
 1) 5.2 5.6 7.1 10.9
Cases/controls 123/1180 105/1181 117/1180 117/1180
Multivariate OR (95% CI) 1.00 0.90 (0.68–1.19) 0.97 (0.74–1.28) 0.83 (0.62–1.11) 0.22
trans-FAs
Median (gday
 1) 0.3 0.6 1.1 2.8
Cases/controls 97/1180 114/1181 123/1180 128/1180
Multivariate OR (95% CI) 1.00 1.21 (0.90–1.62) 1.21 (0.90–1.62) 1.08 (0.80–1.44) 0.50
aFA¼fatty acid; OR¼odds ratio; CI¼confidence interval. Odds ratios and 95% confidence intervals from the logistic regression model adjusted for age, province, educational
attainment, smoking, BMI, total fat and energy intake.
Table 4 ORs
a and 95% CIs for pancreatic cancer associated with saturated and monounsaturated fatty acids and body mass index
Body mass index Fatty acids
Quartiles of fatty acid intakes
P-trend Q1 Q2 Q3 Q4
o25 Stearic acid 1.00 0.95 (0.61–1.48) 1.19 (0.78–1.81) 0.71 (0.43–1.17) 0.54
Oleic acid 0.96 (0.62–1.48) 0.92 (0.60–1.42) 0.76 (0.46–1.25) 0.28
Saturated FAs 1.12 (0.72–1.73) 1.08 (0.70–1.68) 0.79 (0.49–1.27) 0.44
Monounsaturated FAs 0.93 (0.61–1.44) 0.91 (0.59–1.41) 0.76 (0.46–1.26) 0.30
25–29.9 Stearic acid 1.00 0.79 (0.50–1.26) 0.81 (0.51–1.29) 0.95 (0.58–1.55) 0.87
Oleic acid 1.02 (0.64–1.63) 0.88 (0.55–1.42) 1.10 (0.67–1.82) 0.90
Saturated FAs 0.92 (0.58–1.45) 0.82 (0.52–1.30) 0.84 (0.51–1.37) 0.48
Monounsaturated FAs 0.93 (0.59–1.47) 0.84 (0.52–1.35) 1.07 (0.64–1.76) 0.97
X30 Stearic acid 1.00 0.62 (0.34–1.14) 0.38 (0.20–0.74) 0.36 (0.18–0.70) 0.001
Oleic acid 0.67 (0.36–1.23) 0.36 (0.18–0.72) 0.36 (0.19–0.72) 0.002
Saturated FAs 0.40 (0.21–0.76) 0.42 (0.23–0.79) 0.35 (0.18–0.67) 0.002
Monounsaturated FAs 0.72 (0.39–1.31) 0.37 (0.19–0.73) 0.32 (0.16–0.61) 0.001
aFA¼fatty acid. Odds ratios and 95% confidence intervals from the logistic regression model adjusted for age, province, educational attainment, smoking, total fat and energy
intake.
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ymonounsaturated FA intakes were associated with strong and
significantly decreased pancreatic cancer risk in obese subjects
(BMIX30), with 65 and 68% risk reductions, respectively. A cohort
study of pancreatic cancer indicated that dietary glycaemic load
and the glycaemic index are associated with increased risk of
pancreatic cancer among women who were overweight, and among
obese women with low physical activity (Michaud et al, 2002).
Obesity is a physiological state that is accompanied by abnormal
glucose metabolism and greater insulin resistance. Since the
pharmacokinetic properties of both saturated and monounsatu-
rated FAs are not known to depend on BMI, it is likely that obese
subjects may be particularly susceptible to the type of FA they
consume, likely because of some degree of repression of CCK
release. However, the significance of such susceptibility is
speculative and remains to be established.
The major strengths of our study included the large number of
pancreatic cancer cases, histological diagnosis, and general
population sampling of controls. The large sample size permitted
subgroup analyses. Histological confirmation of diagnosis reduced
the possibility of disease misclassification, while a population-
based approach facilitates extrapolation of results to the general
population.
Our study is also subject to certain limitations. Since the
assessment of dietary exposure was retrospective, recall bias cannot
be completely excluded. A prospective cohort approach has several
advantages when studying associations between nutritional factors
and cancer risk. However, because of the relatively low incidence of
pancreatic cancer, the largest cohort to date examining diet and
pancreatic cancer risk confirmed only 178 pancreatic cancer cases
in 18 years of follow-up (Michaud et al, 2003).
We could not adjust OR estimates for the potentially confounding
effects of diabetes mellitus and family history of pancreatic cancer,
since this information was not collected at baseline. Nevertheless, we
expected that diabetes did not confound the association between
specific FA intakes and pancreatic cancer risk because of the
likelihood that diet represents the initial risk factor for both chronic
diseases, rather than lying on the causal pathway. In addition, it has
been suggested that diabetes might be one of the early manifesta-
tions of pancreatic cancer, and the significance of diabetes is much
weaker if cases of recent onset are excluded (WHO/AIRC, 2003). As
well, it is unlikely that the confounding effect of family aggregation
of pancreatic cancer may explain the significantly inverse associa-
tions we found because genetic/familial predisposition is rare
(Ghadirian et al, 2003). Another limitation is the consequence of
early and high case fatality associated with the disease. As in other
epidemiological studies of pancreatic cancer, cases died before the
questionnaire could be administered were not included in the
analysis. However, since there was no discrimination in the selection
of study subjects based on their demographic characteristics and
lifestyle factors, such as age, smoking or educational attainment,
survivors are still representative of the study population. Conse-
quently, bias of this kind, if any, is unlikely to be substantial.
In conclusion, our current analyses suggest that, independently
of total energy intake, substituting polyunsaturated FAs with
saturated or monounsaturated FAs may reduce pancreatic cancer
risk, particularly in subjects who are obese. Further epidemiolo-
gical studies assessing the role of specific dietary FA intakes in the
aetiology of pancreatic cancer are warranted.
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